Logo
Bg pattern

FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Contents of the leaflet

  1. Introduction
  2. What is Fulvestrant Hikma and what is it used for
  3. What you need to know before you use Fulvestrant Hikma
  4. How to use Fulvestrant Hikma
  5. Possible side effects
  6. Storage of Fulvestrant Hikma
  7. Contents of the pack and other information

Introduction

Package Leaflet: Information for the Patient

Fulvestrant Hikma 250 mg solution for injection in pre-filled syringe EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
    • If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Fulvestrant Hikma and what is it used for
  2. What you need to know before you use Fulvestrant Hikma
  3. How to use Fulvestrant Hikma
  4. Possible side effects
  5. Storage of Fulvestrant Hikma
  6. Contents of the pack and other information

1. What is Fulvestrant Hikma and what is it used for

This medicine contains the active substance fulvestrant, which belongs to the group of estrogen blockers. Estrogens, a type of female sex hormone, may be involved in the development of breast cancer in some cases.

Fulvestrant is used:

  • as monotherapy, for the treatment of postmenopausal women with a type of breast cancer called hormone receptor-positive breast cancer, which is locally advanced or has spread to other parts of the body (metastatic), or
  • in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer, which is locally advanced or has spread to other parts of the body (metastatic). Women who have not reached menopause will also be treated with a medicine called luteinizing hormone-releasing hormone (LHRH) agonist.

When Fulvestrant is administered in combination with palbociclib, it is important that you also read the package leaflet of palbociclib. If you have any questions about palbociclib, ask your doctor.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Fulvestrant Hikma

Do not useFulvestrant Hikma:

  • if you are allergic to fulvestrant or any of the other ingredients of this medicine (listed in section 6),
  • if you are pregnant or breastfeeding,
  • if you have severe liver problems.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you start using Fulvestrant Hikma if any of the following apply to you:

  • kidney or liver problems,
  • low platelet count (which helps blood to clot) or bleeding disorders,
  • previous blood clot problems,
  • osteoporosis (loss of bone density),
  • alcoholism.

Children and adolescents

Fulvestrant is not indicated in children and adolescents under 18 years of age.

Other medicines and Fulvestrant Hikma

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In particular, you should tell your doctor if you are using anticoagulants (medicines to prevent blood clots).

Pregnancy and breastfeeding

You should not use this medicine if you are pregnant. If you can become pregnant, you should use an effective contraceptive method while you are being treated with this medicine and for 2 years after the last dose.

You should not breastfeed while you are being treated with Fulvestrant Hikma.

Driving and using machines

This medicine is not expected to affect your ability to drive or use machines. However, if you feel tired after treatment, do not drive or use machines.

Use in athletes

This medicine contains fulvestrant, which may produce a positive result in doping tests.

Fulvestrant Hikma contains ethanol

This medicine contains 10% w/v ethanol (alcohol), i.e., up to 500 mg in each syringe, which is equivalent to 10 ml of beer or 4 ml of wine.

This medicine is harmful to people with alcoholism. To be taken into account in high-risk groups, such as patients with liver disease or epilepsy.

Fulvestrant Hikma contains alcohol (ethanol)

This medicine contains 500 mg of alcohol (ethanol) in each syringe, which is equivalent to 100 mg/ml (10% w/v). The amount in one injection of this medicine is equivalent to less than 13 ml of beer or 5 ml of wine.

The amount of alcohol in this medicine is unlikely to have an effect in adults and adolescents. The alcohol in this medicine may alter the effects of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.

If you are addicted to alcohol, talk to your doctor or pharmacist before taking this medicine.

Fulvestrant Hikma contains benzyl alcohol

This medicine contains 500 mg of benzyl alcohol in each pre-filled syringe, equivalent to 100 mg/ml. Benzyl alcohol may cause allergic reactions.

Talk to your doctor or pharmacist if you have liver or kidney disease. This is because large amounts of benzyl alcohol may accumulate in the body and cause side effects (metabolic acidosis).

Fulvestrant Hikma contains benzyl benzoate

This medicine contains 750 mg of benzyl benzoate per injection, equivalent to 150 mg/ml.

3. How to use Fulvestrant Hikma

Follow exactly the administration instructions of this medicine as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

The recommended dose is 500 mg of fulvestrant (two 250 mg/5ml injections) administered once a month with an additional dose of 500 mg administered 2 weeks after the initial dose.

Your doctor or nurse will administer Fulvestrant Hikma by slow intramuscular injection into each of your buttocks.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You may need urgent medical treatment if you experience any of the following side effects:

  • allergic reactions (hypersensitivity), including swelling of the face, lips, tongue, and/or throat, which may be symptoms of anaphylactic reactions,
  • thromboembolism (increased risk of blood clots),
  • liver inflammation (hepatitis),
  • liver failure.

Tell your doctor, pharmacist, or nurse immediately if you notice any of the following side effects:

Very common side effects(may affect more than 1 in 10 patients)

  • injection site reactions, such as pain and/or inflammation,
  • abnormal liver enzyme levels (in blood tests),
  • nausea (feeling sick),
  • weakness, tiredness,
  • joint and musculoskeletal pain,
  • hot flushes,
  • skin rash,
  • allergic reactions (hypersensitivity), including swelling of the face, lips, tongue, and/or throat.

All other side effects:

Common side effects(may affect up to 1 in 10 patients)

  • headache,
  • vomiting, diarrhea, or loss of appetite,
  • urinary tract infections,
  • back pain,
  • increased bilirubin (a bile pigment produced by the liver),
  • thromboembolism (increased risk of blood clots),
  • low platelet count (thrombocytopenia),
  • vaginal bleeding,
  • lower back pain radiating to one leg (sciatica),
  • sudden weakness, numbness, tingling, or loss of movement in your leg, especially on one side of the body, sudden problems with walking or balance (peripheral neuropathy).

Uncommon side effects(may affect up to 1 in 100 patients)

  • thick, white, vaginal discharge and candidiasis (infection),
  • hematoma and bleeding at the injection site,
  • increased gamma-GT, a liver enzyme that is identified in a blood test,
  • liver inflammation (hepatitis),
  • liver failure,
  • numbness, tingling, and pain,
  • anaphylactic reactions.
  • Includes side effects for which the exact role of fulvestrant cannot be evaluated due to the underlying disease.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website (http://www.aemps.gob.es/). By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Fulvestrant Hikma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or syringe label after EXP. The expiry date refers to the last day of the month shown.

Store and transport refrigerated (between 2°C and 8°C).

Temperature variations outside 2°C - 8°C should be limited. This includes avoiding storage at temperatures above 30°C and not exceeding a period of 28 days in which the average storage temperature of the product is below 25°C (but above 2°C - 8°C). After temperature variations, the product should be returned immediately to the recommended storage conditions (store and transport in a refrigerator between 2°C and 8°C). Temperature variations have a cumulative effect on the quality of the product and the 28-day period should not be exceeded during the validity period of Fulvestrant Hikma. Exposure to temperatures below 2°C will not damage the product as long as it is not stored below -20°C.

Keep the pre-filled syringe in the original packaging to protect it from light.

Your healthcare professional will be responsible for the proper storage, use, and disposal of Fulvestrant Hikma.

This medicine may pose a risk to the aquatic environment. Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

Composition of Fulvestrant Hikma

  • The active substance is fulvestrant. Each pre-filled syringe (5 ml) contains 250 mg of fulvestrant.
  • The other ingredients are ethanol (96%), benzyl alcohol, benzyl benzoate, and refined castor oil.

Appearance and pack contents

Fulvestrant Hikma is a viscous, clear, colorless to yellow solution in a pre-filled syringe containing 5 ml of injectable solution. Two syringes should be administered to receive the recommended monthly dose of 500 mg.

The packs of Fulvestrant Hikma contain 1 or 2 pre-filled syringes. Safety needles (BD SafetyGlide) are also provided for connection to the syringe body.

In addition to individual packs, Fulvestrant Hikma is also available in packs of 4 (2x2) and 6 (3x2) pre-filled syringes.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder:

Hikma Farmacêutica (Portugal), S.A.

Estrada do Rio da Mó n.º 8, 8A e 8B, Fervença

2705-906 Terrugem SNT

Portugal

Email: [email protected]

Manufacturer

Netpharmalab Consulting Services

Carretera de Fuencarral, 22

28108 – Alcobendas, Madrid

Spain

You can ask for more information about this medicine by contacting the local representative of the marketing authorization holder:

Hikma España, S.L.U.

Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2

28108 - Alcobendas, Madrid

Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Germany: Fulvestrant Ribosepharm 250 mg/5 ml solution for injection in a pre-filled syringe

Austria: Fulvestrant Ribosepharm 250 mg/5 ml solution for injection in a pre-filled syringe

Spain: Fulvestrant Hikma 250 mg solution for injection in pre-filled syringe EFG

France: FULVESTRANT HIKMA 250 mg, solution for injection in a pre-filled syringe

Italy: Fulvestrant Hikma

Portugal: Fulvestrant Hikma

Date of last revision of this leaflet: January 2023

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es/)

------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Fulvestrant Hikma 500 mg (2 x 250 mg/5 ml solution for injection) should be administered using two pre-filled syringes. See section 3.

BD SafetyGlide is a registered trademark of Becton Dickinson and Company and its CE-marked: CE 0050.

Administration instructions

Warning – Do not autoclave the safety needle (BD SafetyGlide hypodermic safety needle) before use. Hands should remain behind the needle at all times during use and disposal.

For each of the two syringes:

  • Remove the glass cylinder from the syringe from the tray and check that it is not damaged.
  • Remove the outer packaging of the safety needle (SafetyGlide).
  • Parenteral solutions should be inspected visually for particles and discoloration before administration.
  • Hold the syringe in a vertical position over the grooved part (C). With the other hand, grasp the cap (A) and carefully turn the rigid plastic cap counterclockwise. (see Figure 1)

Hand holding an injection device with labeled parts A, B, and C showing connection and transparent cylinderFigure 1

  • Remove the rigid plastic cap (A) in a straight upward direction. To maintain sterility, do not touch the syringe tip (B) (see Figure 2)

Hand holding an injection device with labeled parts A, B, and C showing cylinder, connector, and cylindrical baseFigure 2

  • Connect the safety needle to the Luer-Lok and turn it until it is firmly seated (see Figure 3).
  • Check that the needle is locked in the Luer connector before leaving the vertical plane.
  • Remove the needle protector to avoid damaging the needle tip.
  • Take the filled syringe to the injection site.
  • Remove the needle sheath.
  • Expel excess air from the syringe.

Gloved hands holding and preparing a syringe with connected needle and a vial of white medicineFigure 3

  • Administer slowly (1-2 minutes/injection) by intramuscular injection into the buttock (gluteal area). For user comfort, the bevel of the needle is oriented towards the lever arm (see Figure 4).

Connected needle to a device with cylinder and plunger, showing an enlarged circle of the beveled needle tipFigure 4

? After injection, immediately touch the lever arm with your finger to activate the safety mechanism (see Figure 5).

NOTE: Activate it away from your body and others. Listen for the click and visually confirm that the needle tip is fully protected.

Hand holding a syringe with connected needle, showing the skin pinching technique for injectionFigure 5

Disposal

The pre-filled syringes are for single use.

This medicine may pose a risk to the aquatic environment. Any unused medicine or waste material should be disposed of in accordance with local requirements.

Online doctors for FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Discuss questions about FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (112)
Doctor

Roman Raevskii

General medicine 7 years exp.

Dr. Roman Raevskii is a licensed general practitioner in Spain, offering online medical consultations with a strong focus on prevention, early diagnosis, and personalized care. He combines evidence-based clinical expertise with a patient-centered approach to deliver comprehensive support.

Dr. Raevskii provides medical care in the following areas:

  • Diagnosis and management of common conditions: hypertension, diabetes, respiratory and digestive disorders.
  • Oncological consultations: early cancer detection, risk evaluation, and treatment navigation.
  • Supportive care for oncology patients – pain control, symptom relief, and side effect management.
  • Preventive medicine and health screenings.
  • Development of tailored treatment plans based on clinical guidelines.

With a patient-centred approach, Dr. Raevskii helps individuals manage both chronic illnesses and complex oncological cases. His consultations are guided by current medical standards and adapted to each patient’s needs.
Camera Book a video appointment
€55
5.0 (9)
Doctor

Iryna Reznychenko

Gynecology 26 years exp.

Dr Iryna Reznychenko is an obstetrician-gynaecologist, paediatric gynaecologist, and certified lactation consultant. She provides online consultations for women at all stages of life – from adolescence to menopause. Her work combines medical care for gynaecological conditions with dedicated support for breastfeeding challenges, both physical and emotional.

Areas of expertise:

  • interpretation of test results and personalised treatment planning
  • menstrual irregularities, PCOS, endometriosis
  • abnormal uterine bleeding, endometrial hyperplasia, cervical dysplasia
  • care during perimenopause and menopause, hormonal balance, cancer prevention
  • breastfeeding issues: nipple pain, cracked skin, blocked ducts, low milk supply
  • support during the postpartum and lactation period
Dr Reznychenko offers a clear, attentive and professional approach. Her consultations help prevent minor discomforts from developing into more serious concerns – all in a convenient online format.
Camera Book a video appointment
€55
5.0 (11)
Doctor

Mar Tabeshadze

Endocrinology 11 years exp.

Dr. Mar Tabeshadze is a licensed endocrinologist and general practitioner in Spain. She provides online consultations for adults, offering medical support for a wide range of endocrine conditions and related health concerns.

  • Diagnostic consultations for suspected endocrine disorders
  • Management of thyroid conditions, including in pregnant women
  • Early detection and treatment of type 1 and type 2 diabetes, with personalised therapy plans
  • Obesity treatment: identifying underlying causes of weight gain, combining medication and non-pharmacological strategies, and long-term support
  • Diagnosis and treatment of endocrine-related skin, hair, and nail issues
  • Ongoing care for patients with osteoporosis, pituitary, and adrenal gland disorders
Dr. Tabeshadze takes a patient-centred approach based on evidence-based medicine. Her goal is to help patients achieve hormonal balance, manage chronic conditions effectively, and improve overall well-being through targeted, personalised care.
Camera Book a video appointment
€55
5.0 (21)
Doctor

Giorgi Eremeishvili

Urology 22 years exp.

Giorgi Eremeishvili is a top-category urologist, a Candidate of Medical Sciences, and a licensed physician in Spain. He provides expert assistance in the diagnosis and treatment of a wide range of urological conditions in both men and women, employing a comprehensive approach and evidence-based principles.

Key areas of expertise:

  • Erectile dysfunction, decreased libido, premature ejaculation.
  • Male infertility: comprehensive diagnosis and modern treatment methods.
  • Prostate gland diseases: acute and chronic prostatitis, prostatic adenoma (benign prostatic hyperplasia), prostate cancer.
  • Inflammatory diseases of the genitourinary system: acute and chronic cystitis, pyelonephritis, epididymitis, orchitis, urethritis.
  • Sexually transmitted infections (STIs): chlamydia, ureaplasmosis, mycoplasmosis, gardnerellosis, candidiasis, herpetic infections, HPV, CMV, trichomoniasis, and others.
  • Urination disorders: urinary retention, frequent urination, urinary incontinence, overactive bladder, neurogenic bladder.
  • Neoplasms: cysts, tumors of the kidneys, bladder, testicles, prostate gland (including prostate cancer).
  • Surgical interventions: determining indications and selecting optimal minimally invasive methods.

Dr. Eremeishvili applies an integrated approach to each case. This includes thorough preoperative preparation, postoperative observation, and regular dynamic follow-up during the treatment process to achieve the best possible outcomes. All diagnostic and therapeutic recommendations are based on current evidence-based medicine and comply with the recommendations of the European Association of Urology, guaranteeing high-quality and effective care.

If you are seeking qualified assistance in diagnosing or treating urological conditions, book an online consultation with Dr. Giorgi Eremeishvili. Get expert support, accurate diagnosis, and a personalized treatment plan from the comfort of your home.
Camera Book a video appointment
€60
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60
5.0 (29)
Doctor

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

  • Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
  • Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
  • Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
  • Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
  • General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
  • Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
  • Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
  • Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.
Camera Book a video appointment
€60
0.0 (2)
Doctor

Marianna Neshta

Endocrinology 25 years exp.

Marianna Neshta is a medical doctor specialising in endocrinology and ultrasound diagnostics. She provides online consultations for adults, focusing on the diagnosis, treatment, and long-term management of endocrine disorders. Her approach includes personalised care plans, analysis of lab results and ultrasound scans, and evidence-based treatment.

Key areas of expertise:

  • Type 1 and Type 2 diabetes – diagnosis, therapy adjustment, CGM interpretation, and prevention of chronic complications
  • Obesity – treatment using both medication and lifestyle strategies, including modern GLP-1 medications and tailored follow-up plans
  • Thyroid disorders – ultrasound assessment, treatment planning, and management during pregnancy
  • Male hypogonadism – age-related or hormonal, including diagnostics and therapy
  • Metabolic syndrome, prediabetes, lipid disorders – risk assessment, lifestyle recommendations, and medical treatment
  • Calcium metabolism disorders – diagnosis and management of osteoporosis, hyperparathyroidism, and hypoparathyroidism
Dr Neshta applies current clinical guidelines and diagnostic tools, offering medical support adapted to each patient’s individual needs — all in an accessible online format.
Camera Book a video appointment
€45

Frequently Asked Questions

Is a prescription required for FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
The active ingredient in FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is fulvestrant. This information helps identify medicines with the same composition but different brand names.
Who manufactures FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is manufactured by Hikma Farmaceutica (Portugal) S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to FULVESTRANT HIKMA 250 mg READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
Other medicines with the same active substance (fulvestrant) include AFULTRANT 250 mg Injectable Solution in Pre-filled Syringe, AMBIFUL 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, FASLODEX 250 mg/5 ml INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.
Follow us on social media